ODAC Says Toxicity Trumps Meager PFS And TTP Benefit for Yondelis, Doxil
Executive Summary
Changing endpoints midway through the clinical trials for the two Centocor/Ortho Biotech oncology drugs reviewed by FDA's Oncologic Drugs Advisory Committee July 15 did not help their regulatory prospects - but in the end it was the poor efficacy and unacceptable toxicity that doomed both Yondelis and Doxil
You may also be interested in...
Two In One Day: Centocor Ortho Biotech Gets Complete Response Letters For Doxil In Breast Cancer And Yondelis In Ovarian Cancer
For Yondelis, FDA has requested mature overall survival data from an ongoing pivotal trial. For Doxil, it is likely another trial will be necessary.
Marine-Based Drugs Face Choppy Waters, But 13 Compounds In Clinical Trials
When an FDA advisory committee voted against approval of Yondelis (trabectedin) for treatment of relapsed ovarian cancer, drug sponsor Centocor/Ortho Biotech wasn't the only one that was disappointed. Researchers focused on marine natural products have been tracking Yondelis, one of the leading sea-based compounds, and its clearance in the U.S. would have been a boon for their field.
Marine-Based Drugs Face Choppy Waters, But 13 Compounds In Clinical Trials
When an FDA advisory committee voted against approval of Yondelis (trabectedin) for treatment of relapsed ovarian cancer, drug sponsor Centocor/Ortho Biotech wasn't the only one that was disappointed. Researchers focused on marine natural products have been tracking Yondelis, one of the leading sea-based compounds, and its clearance in the U.S. would have been a boon for their field.